Date and time requested: January 21, 2015 at 11:30 AM
Date and time answered: February 28, 2015 at 3:00 PM
Describe the role of Trulicity in the management of type 2 DM. What does the evidence show and its place in therapy?
Background In the United States, approximately 25.8 million people have diabetes. Of the 25.8 million people, about 5% to 10% have type 1 diabetes and 90% to 95% have type 2 diabetes (T2DM).1 The prevalence of diabetes is much higher in non-Hispanic white, American Indian and African American and lower in Hispanic and Asian.1 Majority of the worldwide diabetic patients are type 2 diabetes which means they are insulin resistant. Insulin is important in lowering blood glucose by bringing in glucose inside the cells. If their bodies are resistant to insulin, there will be less glucose going into the cells and more glucose in the blood which indicate a high hemoglobin A1c level (HbA1c).2 HbA1c level above 7% will increase the risk for artery diseases, stroke, diabetic neuropathy, nephropathy, and retinopathy. Therefore, treatments are …show more content…
The first trial conducted by Grunberger et al included 167 patients with type 2 diabetes for 3.9 years with A1c of 7.2 ± 0.6% who were on metformin or had failed metformin.3 The patients were either taking a placebo, dulaglutide 0.1 mg, dulaglutide 0.5 mg, dulaglutide 1 mg, dulaglutide 1.5 mg. The results showed that patients in each of the dulaglutide treatments had significant (p-value <0.001) A1c reduction, with 75% of the patients in each treatment reaching A1c <7% and 50% reaching A1c <6.5%, except the 0.1 mg dose.3 dulaglutide also decreased fasting plasma glucose (FPG) more than 26 mg/dL, except using the 0.1 mg
Date and time answered: February 28, 2015 at 3:00 PM
Describe the role of Trulicity in the management of type 2 DM. What does the evidence show and its place in therapy?
Background In the United States, approximately 25.8 million people have diabetes. Of the 25.8 million people, about 5% to 10% have type 1 diabetes and 90% to 95% have type 2 diabetes (T2DM).1 The prevalence of diabetes is much higher in non-Hispanic white, American Indian and African American and lower in Hispanic and Asian.1 Majority of the worldwide diabetic patients are type 2 diabetes which means they are insulin resistant. Insulin is important in lowering blood glucose by bringing in glucose inside the cells. If their bodies are resistant to insulin, there will be less glucose going into the cells and more glucose in the blood which indicate a high hemoglobin A1c level (HbA1c).2 HbA1c level above 7% will increase the risk for artery diseases, stroke, diabetic neuropathy, nephropathy, and retinopathy. Therefore, treatments are …show more content…
The first trial conducted by Grunberger et al included 167 patients with type 2 diabetes for 3.9 years with A1c of 7.2 ± 0.6% who were on metformin or had failed metformin.3 The patients were either taking a placebo, dulaglutide 0.1 mg, dulaglutide 0.5 mg, dulaglutide 1 mg, dulaglutide 1.5 mg. The results showed that patients in each of the dulaglutide treatments had significant (p-value <0.001) A1c reduction, with 75% of the patients in each treatment reaching A1c <7% and 50% reaching A1c <6.5%, except the 0.1 mg dose.3 dulaglutide also decreased fasting plasma glucose (FPG) more than 26 mg/dL, except using the 0.1 mg